FDA chooses 20 diseases to focus on, but not amyloidosis

I confess I am disappointed in the choices made by the FDA for its patient-focused drug development program:


A couple of choices, such as breast and lung cancer, already have plenty of R & D resources, and a couple of others seem like trivial conditions compared to diseases like lupus or amyloidosis.

I know ga_peach worked hard on this issue, and I hope we can be part of the effort in 2016 to have amyloidosis included next time.